慢性乙型肝炎免疫耐受期可有条件接受抗病毒治疗

肖丽; 咸建春

doi:10.3969/j.issn.1001-5256.2021.04.010

慢性乙型肝炎免疫耐受期可有条件接受抗病毒治疗

DOI: 10.3969/j.issn.1001-5256.2021.04.010

肖丽,
咸建春^,

泰州市人民医院肝病科，江苏泰州 225300

详细信息

作者简介:
肖丽(1979—)，女，博士，科副主任，主要从事病毒性肝炎、疑难危重肝病方面的研究

通信作者:
咸建春，xianjc09@163.com

中图分类号: R512.62
计量
- 文章访问数: 380
- HTML全文浏览量: 67
- PDF下载量: 62
- 被引次数: 0
出版历程
- 收稿日期: 2021-02-02
- 录用日期: 2021-02-28
- 出版日期: 2021-04-20

Patients in the immune-tolerant phase of chronic hepatitis B can receive antiviral therapy conditionally

Li XIAO,
Jianchun XIAN^,

Department of Hepatology, Taizhou People's Hospital, Taizhou, Jiangsu 225300, China

摘要

- 乙型肝炎病毒 /
- 乙型肝炎，慢性 /
- 免疫耐受 /
- 治疗学
- Hepatitis B virus /
- Hepatitis B, Chronic /
- Immune Tolerance /
- Therapeutics

HTML全文

参考文献(18)

[1]	JONAS MM, LOK AS, MCMAHON BJ, et al. Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis[J]. Hepatology, 2016, 63(1): 307-318. DOI: 10.1002/hep.28278.
[2]	LEE HW, KIM SU, BAATARKHUU O, et al. Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals[J]. Sci Rep, 2019, 9(1): 2508. DOI: 10.1038/s41598-019-39043-2.
[3]	KIM GA, LIM YS, HAN S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B[J]. Gut, 2018, 67(5): 945-952. DOI: 10.1136/gutjnl-2017-314904.
[4]	XIANG X, YOU XM, ZHONG JH, et al. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection[J]. J Hepatol, 2017, 67(4): 885-886. DOI: 10.1016/j.jhep.2017.05.030.
[5]	CHEN CJ, YANG HI, SU J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA, 2006, 295(1): 65-73. DOI: 10.1001/jama.295.1.65.
[6]	CHEN CF, LEE WC, YANG HI, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma[J]. Gastroenterology, 2011, 141(4): 1240-1248. DOI: 10.1053/j.gastro.2011.06.036.
[7]	WANG HY, CHIEN MH, HUANG HP, et al. Distinct hepatitis B virus dynamics in the immunotolerant and early immunoclearance phases[J]. J Virol, 2010, 84(7): 3454-3463. DOI: 10.1128/JVI.02164-09.
[8]	ZOULIM F, MASON WS. Reasons to consider earlier treatment of chronic HBV infections[J]. Gut, 2012, 61(3): 333-336. DOI: 10.1136/gutjnl-2011-300937.
[9]	CLEMENTE MG, VAJRO P. An update on the strategies used for the treatment of chronic hepatitis B in children[J]. Expert Rev Gastroenterol Hepatol, 2016, 10(5): 649-658. DOI: 10.1586/17474124.2016.1139450.
[10]	ARTAN R. Lamivudine monotherapy in children with immune-tolerant chronic hepatitis B virus[J]. J Chemother, 2005, 17(2): 198-202. DOI: 10.1179/joc.2005.17.2.198.
[11]	D'ANTIGA L, AW M, ATKINS M, et al. Combined lamivudine/interferon-alpha treatment in "immunotolerant" children perinatally infected with hepatitis B: A pilot study[J]. J Pediatr, 2006, 148(2): 228-233. DOI: 10.1016/j.jpeds.2005.09.020.
[12]	PODDAR U, YACHHA SK, AGARWAL J, et al. Cure for immune-tolerant hepatitis B in children: Is it an achievable target with sequential combo therapy with lamivudine and interferon?[J]. J Viral Hepat, 2013, 20(5): 311-316. DOI: 10.1111/jvh.12007.
[13]	ROSENTHAL P, LING SC, BELLE SH, et al. Combination of entecavir/peginterferon alfa-2a in children with hepatitis B e antigen-positive immune tolerant chronic hepatitis B virus infection[J]. Hepatology, 2019, 69(6): 2326-2337. DOI: 10.1002/hep.30312.
[14]	FELD JJ, TERRAULT NA, LIN HS, et al. Entecavir and peginterferon alfa-2a in adults with hepatitis B e antigen-positive immune-tolerant chronic hepatitis B virus infection[J]. Hepatology, 2019, 69(6): 2338-2348. DOI: 10.1002/hep.30417.
[15]	CHAN HL, CHAN CK, HUI AJ, et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA[J]. Gastroenterology, 2014, 146(5): 1240-1248. DOI: 10.1053/j.gastro.2014.01.044.
[16]	MARTIN P. Immune-tolerant hepatitis B: Maybe a misnomer but still hard to treat[J]. Hepatology, 2019, 69(6): 2315-2317. DOI: 10.1002/hep.30654.
[17]	WONG VW, HUI AJ, WONG GL, et al. Four-year outcomes after cessation of tenofovir in immune-tolerant chronic hepatitis B patients[J]. J Clin Gastroenterol, 2018, 52(4): 347-352. DOI: 10.1097/MCG.0000000000000852.
[18]	WANG XR, XIAO L, GENG AW, et al. Pegylated interferon for treatment of chronic hepatitis B-induced thrombotic thrombocytopenic purpura: A case report[J]. J Clin Hepatol, 2020, 36(11): 2534-2536. DOI: 10.3969/j.issn.001-5256.2020.11.028. 王欣茹, 肖丽, 耿爱文, 等. 聚乙二醇干扰素治疗慢性乙型肝炎诱发血栓性血小板减少性紫癜1例报告[J]. 临床肝胆病杂志, 2020, 36(11): 2534-2536. DOI: 10.3969/j.issn.1001-5256.2020.11.028.